Reduction in Staphylococcus aureus bacteraemia rates in patients receiving haemodialysis following alteration of skin antisepsis procedures. Issue 2 (February 2016)

• Record Type: Journal Article
• Authors: Stewart, B.J.; Gardiner, T.; Perry, G.J.; Tong, S.Y.C.
• Is Part Of: Journal of hospital infection. Volume 92:Issue 2(2016)
• Page Start: 191
• Page End: 193
• Publication Date: 2016-02
• Subjects: Staphylococcus aureus -- Haemodialysis -- ANZDATA -- Arteriovenous fistula -- Central venous catheter -- Chlorhexidine; Cross infection -- Periodicals; Cross infection -- Prevention -- Periodicals; Nosocomial infections -- Periodicals; Nosocomial infections -- Prevention -- Periodicals; Cross Infection -- Periodicals; Cross Infection -- prevention & control -- Periodicals; Infection Control -- Periodicals; Electronic journals; 614.44
• DOI: 10.1016/j.jhin.2015.10.022
• Languages: English
• ISSNs: 0195-6701

Abstract

Summary: This study examined all cases of Staphylococcus aureus bacteraemia (SAB) in the haemodialysis cohort at the Royal Darwin Hospital, Australia over a seven-year period. Midway through this period, antisepsis for arteriovenous fistulae (AVF) and central venous catheters (CVC) changed from 0.5% chlorhexidine solution to 2% chlorhexidine solution. Rates of SAB episodes were calculated using registry data. Trends in SAB over time were analysed using an interrupted regression analysis. Following the change to 2% chlorhexidine, average SAB rates decreased by 68%, and it is estimated that 0.111 cases of SAB/patient-year were prevented. CVC-related SAB rates remained low throughout. These results support the use of 2% chlorhexidine in skin antisepsis for patients with AVF.